By Daniella Parra
Eterna Therapeutics Inc. (Nasdaq: ERNA) announced the appointment of Brant Binder, a seasoned leader and entrepreneur with more than 25 years of strategic expertise building and growing biotechnology companies and Richard Wagner, Ph.D., a biotechnology entrepreneur with more than 30 years of experience creating and managing drug discovery innovations, to its Board of Directors.
Dr. Wagner said in a statement that it’s an exciting time to join the Eterna Board following its recent scientific and business achievements, as the team at Eterna continues to explore strategic partnerships to expand the reach of its technology.
“I am eager to contribute to Eterna’s momentum as the Company makes progress supporting the development of next-generation mRNA-based therapeutic products. I look forward to bringing my experience working with growth-stage biotechnology companies as Eterna continues to advance its corporate strategy,” Mr. Binder commented.